Literature DB >> 26479189

Better response to the SGLT2 inhibitor dapagliflozin in young adults with type 2 diabetes.

Yuta Nakamura1, Yoshio Nagai1, Yuko Terashima1, Ami Nishine1, Satoshi Ishii1, Hiroyuki Kato1, Akio Ohta1, Yasushi Tanaka1.   

Abstract

BACKGROUND AND AIM: A variation of the response to Sodium glucose co-transporter 2 (SGLT2) inhibitors with age has not been investigated in patients with diabetes. The aim of this study was to assess renal threshold of glucose (RTg) before and after administration of an SGLT2 inhibitor in young adult patients (≤40 years) and older adult patients (>40 years) with type 2 diabetes (T2DM). SUBJECTS AND METHODS: Twenty Japanese patients with T2DM were enrolled. Baseline data were obtained on the first day and dapagliflozin (5 mg) was administered at 6:00 on the second day. Glucose excursions were assessed by continuous glucose monitoring and urine samples were collected every hour during the daytime (7:00 to 15:00) on both days. RTg was estimated from the regression line of the scatter plot of the hourly mean glucose concentrations.
RESULTS: After a single dose of dapagliflozin, RTg decreased from 121.5 to 6.1 mg/dl in the young adult group and from 151.0 mg/dl to -15.8 mg/dl in the older group. After dapagliflozin, the slope of the regression line was significantly steeper in the young adult group.
CONCLUSION: Dapagliflozin was more effective in young patients because they showed a larger response of urinary glucose excretion.

Entities:  

Keywords:  SGLT2 inhibitor; continuous glucose monitoring; dapagliflozin; renal threshold of glucose; type 2 diabetes

Mesh:

Substances:

Year:  2015        PMID: 26479189     DOI: 10.1517/14656566.2015.1101450

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  5 in total

1.  Characteristics and Impact Factors of Renal Threshold for Glucose Excretion in Patients with Type 2 Diabetes Mellitus.

Authors:  Xiao Dan Yue; Jing Yu Wang; Xin Rong Zhang; Ju Hong Yang; Chun Yan Shan; Miao Yan Zheng; Hui Zhu Ren; Yi Zhang; Shao Hua Yang; Zhen Hong Guo; Bai Chang; Bao Cheng Chang
Journal:  J Korean Med Sci       Date:  2017-04       Impact factor: 2.153

2.  A Lower Baseline Urinary Glucose Excretion Predicts a Better Response to the Sodium Glucose Cotransporter 2 Inhibitor.

Authors:  You Cheol Hwang; Jae Hyeon Kim; Byung Wan Lee; Woo Je Lee
Journal:  Diabetes Metab J       Date:  2019-06-14       Impact factor: 5.376

3.  Renal threshold for glucose reabsorption predicts diabetes improvement by sodium-glucose cotransporter 2 inhibitor therapy.

Authors:  Aya Osaki; Shuichi Okada; Tsugumichi Saito; Eijiro Yamada; Kumeo Ono; Yawara Niijima; Hiroto Hoshi; Masanobu Yamada
Journal:  J Diabetes Investig       Date:  2016-02-16       Impact factor: 4.232

4.  Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea.

Authors:  Eugene Han; Ari Kim; Sung Jae Lee; Je-Yon Kim; Jae Hyeon Kim; Woo Je Lee; Byung-Wan Lee
Journal:  Diabetes Ther       Date:  2018-07-11       Impact factor: 2.945

5.  Effect of Insulin on Proximal Tubules Handling of Glucose: A Systematic Review.

Authors:  Ricardo Pereira-Moreira; Elza Muscelli
Journal:  J Diabetes Res       Date:  2020-01-10       Impact factor: 4.011

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.